• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

michael.dickinson@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
Education
Bachelors Degree (Honours)
The University of Western Australia
ORCID

0000-0002-1492-5966

Prof Michael Dickinson

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

271 Scholarly works
1 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
    DOI: 10.1182/blood.2025032307
  • 2026

    Journal article

    Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
    DOI: 10.1182/bloodadvances.2026020123
  • 2026

    Journal article

    Glofitamab monotherapy in patients with Richter's transformation: safety and efficacy from a phase 1 study.
    DOI: 10.1182/bloodadvances.2025018159
  • 2026

    Journal article

    Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.
    DOI: 10.1182/bloodadvances.2026020012
  • 2026

    Journal article

    Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries
    DOI: 10.1182/blood.2025030872
  • 2022

    Research grants (other domestic)

    Novel Strategies to Predict and Monitor Response to CAR T-Cell Therapy in DLBCL
  • 2019

    Journal article

    Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
    DOI: 10.1111/bjh.16069
Michael Dickinson

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Web-Based Cognitive Rehabilitation for Patients With Aggressive Lymphoma With Perceived Cognitive Impairment: A Randomised Pilot Study
    DOI: 10.1002/pon.70469
  • 2026

    Journal article

    Five-Year Update of the Phase 2 ELARA Trial of Tisagenlecleucel in Patients (pts) with relapsed/refractory Follicular Lymphoma (r/r FL)
    DOI: 10.1016/j.jtct.2025.12.077
  • 2026

    Journal article

    The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy
    DOI: 10.1177/17562864251404464
  • 2026

    Journal article

    Bispecific antibody combination therapies in diffuse large B-cell lymphoma
    DOI: 10.1111/bjh.70228
  • 2026

    Journal article

    Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era
    DOI: 10.1111/bjh.70451

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224